《藥物靶向》雜志發(fā)表了關(guān)于藥物傳遞和分子和大分子藥物靶向的所有方面的論文和評論，包括為這些藥物的體外和/或體內(nèi)應(yīng)用設(shè)計和表征載體系統(tǒng)(膠體、蛋白質(zhì)或聚合物)。論文不僅限于通過載體傳遞藥物，還包括針對特定細(xì)胞或細(xì)胞外分子的分子和大分子藥物的研究。因此，該雜志發(fā)表了包括基因/質(zhì)粒DNA、基因沉默核酸(如小干擾RNA、反義寡核苷酸、核糖酶、DNAzymes)、適配體、單核苷酸和單克隆抗體及其偶聯(lián)物在內(nèi)的治療肽/蛋白質(zhì)和核酸的活性、傳遞和靶向性的研究結(jié)果。目標(biāo)技術(shù)的診斷應(yīng)用以及診斷和顯像劑的靶向交付也屬于該雜志的范圍。此外，還尋求關(guān)于自我調(diào)節(jié)系統(tǒng)、對環(huán)境和外部刺激作出反應(yīng)的系統(tǒng)以及能夠產(chǎn)生程控、脈沖和其他復(fù)雜傳遞模式的系統(tǒng)的論文。藥物雜志的目標(biāo)也有論文的生理和其他生物障礙交付和定位,和手段,克服障礙,例如,通過滲透增強(qiáng)劑,并涵蓋科目如溢出,在腫瘤擴(kuò)散和目標(biāo)組織,避免網(wǎng)狀內(nèi)皮系統(tǒng),和小說交付系統(tǒng)的毒性測試和許可。

The Journal of Drug Targeting publishes papers and reviews on all aspects of drug delivery and targeting for molecular and macromolecular drugs including the design and characterization of carrier systems (whether colloidal, protein or polymeric) for both vitro and/or in vivo applications of these drugs. Papers are not restricted to drugs delivered by way of a carrier, but also include studies on molecular and macromolecular drugs that are designed to target specific cellular or extra-cellular molecules. As such the journal publishes results on the activity, delivery and targeting of therapeutic peptides/proteins and nucleic acids including genes/plasmid DNA, gene silencing nucleic acids (e.g. small interfering (si)RNA, antisense oligonucleotides, ribozymes, DNAzymes), as well as aptamers, mononucleotides and monoclonal antibodies and their conjugates. The diagnostic application of targeting technologies as well as targeted delivery of diagnostic and imaging agents also fall within the scope of the journal. In addition, papers are sought on self-regulating systems, systems responsive to their environment and to external stimuli and those that can produce programmed, pulsed and otherwise complex delivery patterns. The Journal of Drug Targeting also carries papers on the physiological and other biological barriers to delivery and targeting, and means of overcoming the barriers, for example, by penetration enhancers, and covers subjects such as extravasation, diffusion in tumours and target tissues, avoidance of the reticulo-endothelial system, and toxicity testing and licensing of novel delivery systems.